ultraviolet radiation cause melanoma in man. Further, there is no direct evidence that 5-methoxypsoralen, which is used in suntan preparations, is carcinogenic or mutagenic, although there are reasons to believe that it might be.² It would be desirable to investigate whether secular changes in sales of suntan preparations containing psoralens are associated with trends in melanoma incidence and whether prior use of such preparations appears as a risk factor in case-control studies.

A J SWERDLOW

Oxford Regional Health Authority,
Oxford OX3 7LF¹ Stern R S, Thibodeau L A, Kleinerman R A, *et al.*
N Engl J Med 1979;300:809-813.² Ashwood-Smith MJ. *Br Med J* 1979;ii:1144.

Supplies of Trilene

SIR,—Last July we announced our intention of discontinuing supplies of Trilene at the end of 1980. The production problems that precipitated that notice have been resolved. In response to the many requests from anaesthetists that we should continue to produce Trilene, we can now assure supplies for at least the next three or four years and, we hope, beyond that.

Supplies will be available through the usual distributors, but if your readers should have any difficulty a note or a telephone call to me will ensure that the matter is dealt with promptly.

A BARNES

Imperial Chemical Industries Limited,
Pharmaceuticals Division (UK Medical
Products Department),
Alderley House,
Alderley Park,
Macclesfield, Cheshire SK10 4TF
(Tel 0625 582828 ext 1139)

Poststreptococcal glomerulonephritis

SIR,—Your leading article on poststreptococcal glomerulonephritis (17 November, p 1243) reviews two recent papers with apparently conflicting views. The first of these, by Baldwin¹ from New York, challenges the belief that the condition follows a benign course in most patients, while the work of Lien *et al*² from South Australia provides support for the more traditional view.

We believe, however, that the data in these papers are compatible. Although 60% of Baldwin's patients show evidence of normal renal disease at two to 18 years compared with only 26% of Lien's patients, followed for one to 14 years, this may be due simply to different methods of study. Baldwin, for example, defined as abnormal any patient with trace proteinuria or reduced inulin clearance, whereas Lien *et al* required protein losses of more than 1 g daily or a raised serum creatinine concentration. It seems hardly surprising therefore that Baldwin observed a greater degree of abnormality.

Direct comparison of those patients with raised serum creatinine concentration is unfortunately complicated by the fact that so few of Baldwin's patients returned for follow-up. He does state nevertheless that 50% of 16 patients seen more than 10 years after their initial illness had a serum creatinine greater than 97 $\mu\text{mol/l}$ (1.1 mg/100 ml). It would be very difficult to draw any conclusions from this about the course of the disease in the other 152 patients in his series. Lien's group

on the other hand managed to trace all of their 57 patients and found only two (3.5%) with serum creatinine greater than 120 $\mu\text{mol/l}$ (1.4 mg/100 ml two or more years after the acute illness.

The histological differences reported, however, do appear to be real, in particular the occurrence of glomerulosclerosis in more than 50% of Baldwin's repeat biopsies and its relative absence from the Australian series. The explanation for this is not entirely clear. The importance of glomerulosclerosis nevertheless rests in its implied association with progressive loss of renal function and it is therefore interesting to note that the incidence of end-stage renal failure was identical—namely, 1.7% for each group.

In conclusion therefore we would like to suggest that, despite the differences in ethnic groups, age range, methods of study, and number of patients available for follow-up, Baldwin's and Lien's papers present essentially similar data for the natural history of post-streptococcal glomerulonephritis. Minor abnormalities of renal function are present in many patients, especially when these are looked for carefully. Progression to terminal renal failure appears to be rare, however, and few patients coming to dialysis are likely to have end-stage poststreptococcal glomerulonephritis as their underlying pathology.

CHRISTOPHER ISLES
MICHAEL BOULTON-JONESRenal Unit,
Royal Infirmary,
Glasgow G4 0SF¹ Baldwin DS. *Am J Med* 1977;62:1-11.² Lien JWK, Mathew TH, Meadows R. *Quart J Med* 1979;48:99-112.

Epileptic drugs and the police

SIR,—A patient of mine, a man of 20, who is an epileptic controlled on anticonvulsants for many years, and with a driving licence issued by the Department of the Environment in full knowledge of his condition, was recently arrested by the police and searched, when his medication was found. He was charged with being in possession of drugs and locked in a cell. His medication was taken away from him and it was only with the utmost difficulty that it was eventually restored to him. It is hardly necessary to point out the danger to which he was exposed—not only the hazard of a convulsion but also the probable loss of his driving licence.

The charge has been withdrawn and the situation is now resolved but it appears that many other epileptics may be in similar danger. I have now given my patient a statement detailing his condition, his medication, and the fact that his driving licence has been issued legally. I consider that it would be desirable for anybody in this young man's condition to have a similar statement and it might be preferable if an official form could be made available for this purpose.

It also seems desirable that police stations should have available a list of drugs used in the treatment of epilepsy (the current *MIMS* lists only 19). In the case I mention the patient's drugs were restored after communication with his mother. She forgot to mention that he is also taking folic acid and this seemed to raise the suspicions of the arresting officer.

J A RIDDLE

Bexley, Kent DA5 1AT

Sustained-release lithium tablets and renal function

SIR,—Drs L Wallin and C Alling (24 November, p 1332) claimed the superiority of sustained-release lithium tablets over conventional tablets on the ground that long-term treatment with the latter preparation lowered renal concentrating ability significantly more than did treatment with the former.

The concentrating ability is a measure of the lithium-induced alteration in renal water reabsorption. The authors compared patient groups that were matched with respect to age, sex, and total intake of lithium. However, the groups were not matched with respect to serum lithium concentration and duration of treatment. According to animal studies¹ and observations on patients (Vestergaard, Thomsen, data to be published), these two variables correlate significantly with the lithium-induced disturbance of water reabsorption, and their variation should consequently be controlled when renal function is investigated. Drs Wallin and Alling have not made it seem probable that their matching criteria sufficiently controlled the variation in all relevant treatment variables but the one under investigation. Sustained-release tablets may or may not be preferable to conventional tablets, but the evidence presented hardly decides this issue.

PER VESTERGAARD

Psychopharmacology Research Unit,
Aarhus University Institute of Psychiatry,
DK-8240 Risskov,
Denmark¹ Thomsen K. *J Pharmacol Exp Ther* 1976;199:483-9.

Psychoanalysis, psychotherapy, and health services

SIR,—It is hard to know what to make of Professor M Shepherd's paper (15 December, p 1557). He quite correctly points out that the public is entitled to decide how far it will support health care for the community at large. In this context, cost-benefit analysis may well override considerations of efficacy. Can we, for example, afford renal dialysis and intensive care units? Similarly, his call for scientific objectivity and freedom from vested interest in psychiatric investigation makes good sense.

It is, however, difficult to align these attitudes with what I take to be the main thrust of his paper. How are we to understand his attack on psychoanalysis and psychotherapy? I cannot believe that a man of his reputation is unfamiliar with the extensive and significant literature on psychotherapy research available in this and other countries, and yet in support of his own critical view he uses references from *Time* magazine, an psychoanalyst named Appelbaum, and an out-of-context quote from D H Lawrence.

How can we understand his criticism of a lack of clarity and objectivity in others when it is impossible to discern whether he is espousing an abandoning of the dynamic therapies or whether he wishes us to abandon the whole of psychodynamic theory so that we can start afresh? Certainly he seems keen to support the embittered Janet's concept of psychoanalysis as "A mental liquidation" and *Time* magazine's accusation that psychoanalysis is alone responsible for the "narcissistic excesses of today's Me decade."

Professor Shepherd's concern for the